Halozyme Therapeutics (NASDAQ:HALO) Stock Sale Revealed by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Halozyme Therapeutics stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Halozyme Therapeutics Trading Down 1.3%

HALO opened at $109.62 on Wednesday. The firm’s fifty day moving average price is $107.30 and its 200 day moving average price is $83.87. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $116.85. The stock has a market capitalization of $12.44 billion, a PE ratio of 32.72, a P/E/G ratio of 0.42 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same period in the prior year, the company earned $1.54 earnings per share. The business’s revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current fiscal year.

Analyst Ratings Changes

HALO has been the topic of several research reports. JPMorgan Chase & Co. upped their price target on Halozyme Therapeutics from $70.00 to $78.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. TD Cowen lifted their price target on Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Finally, Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.50.

Insider Activity

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 18,996 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the completion of the sale, the director directly owned 58,839 shares in the company, valued at $6,339,313.86. This represents a 24.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at $82,482,605.40. The trade was a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 125,852 shares of company stock valued at $13,538,046 over the last 90 days. 2.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Institutional investors have recently bought and sold shares of the stock. Signal Advisors Wealth LLC bought a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $850,000. B. Riley Wealth Advisors Inc. bought a new stake in Halozyme Therapeutics during the third quarter worth approximately $232,000. Cooper Investors PTY Ltd. boosted its position in Halozyme Therapeutics by 19.8% during the third quarter. Cooper Investors PTY Ltd. now owns 65,933 shares of the biopharmaceutical company’s stock worth $7,279,000 after purchasing an additional 10,910 shares during the period. NorthCrest Asset Manangement LLC grew its holdings in Halozyme Therapeutics by 27.7% during the third quarter. NorthCrest Asset Manangement LLC now owns 57,661 shares of the biopharmaceutical company’s stock valued at $6,333,000 after purchasing an additional 12,511 shares during the last quarter. Finally, GK Wealth Management LLC acquired a new position in Halozyme Therapeutics during the third quarter valued at approximately $178,000. 97.79% of the stock is currently owned by institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.